Personalized Genomic Vaccine Appeared Safe, Induced Immunogenicity Among Patients With Different Cancers At High Risk For Recurrence

Healio (4/13, Lawrence) reports that “a personalized genomic vaccine administered after standard-of-care adjuvant therapy appeared safe and induced immunogenicity among patients with different cancers at a high risk for recurrence, according to results of a phase 1 trial.” The research, “presented at the virtual American Association for Cancer Research Annual Meeting, also showed feasibility of developing the neoantigen cancer vaccine, PGV-001, using Mount Sinai’s computational platform, OpenVax.”